QRxPharma Limited (ASX: QRX) was listed on the Australian Securities Exchange (ASX) and OTCQX: QRXPY. On 22 May 2015 the shares of the Company were suspended from trading on the ASX and the company has been delisted.
The principal activities of the company was the development and commercialisation of biopharmaceutical products.
A Deed of Company Arrangement (DOCA) was wholly effectuated on 23 December 2015 returning the management and control of the Company to the Board. The Board is now in a position where all historic liabilities have been accounted for including through the DOCA process and the future focus is identifying the business opportunities that will assist the reinstatement of the Company’s securities to official quotation on the Australian Securities Exchange.
